Maximize Your Health Savings Account By Eating The Right Foods
By Wiley Long
The people who will have the most money in their Health Savings Account are those who fully fund it, put the money in well-performing mutual funds, and stay healthy so they can avoid making premature withdrawals. Diet is the foundation of good health, and the healthiest diet you can eat is the one we evolved to eat, commonly known as The Paleo Diet.

Choose Not To Get Sick

One thing that most Health Savings Account owners have in common is a belief in personal responsibility. They know that if they depend on the government to pay their medical bills in their old age, they‘ll be at the mercy of a government bureaucrat, and their choices will be limited. So instead they choose to put money aside each year to cover future expenses. As a thank you, the government provides a nice tax write-off, tax-deferred growth, and tax-free medical spending.

The other area where most people can take more personal responsibility is with their health. People tend to have the attitude that “stuff happens“, and there‘s not much you can do to prevent the degenerative diseases that come with aging. This is hogwash.

Longevity has advanced dramatically in the past century. Some of this is due to new drugs and advances in surgical techniques. But most of it is simply lifestyle - people are bathing more frequently, they are working under less dangerous conditions, they are smoking less, and some are eating better food. (Fresh fruits and vegetables were rare and expensive during winter months when my grandfather was a child).

Other than not smoking cigarettes, the most powerful thing you can do to ensure good health is to eat the right foods. Most people get it wrong, but if you follow this advice you will lower your risk of almost all the diseases and disorders that disrupt the lifestyle and drain the bank accounts of so many people when they reach their 50‘s, 60‘s, and 70‘s.

Why Is Nutrition So Confusing?

In 1988, Surgeon General, C. Everett Koop announced that high-fat foods in the American diet had a health risk that was comparable to cigarette smoking. So people began eating no-fat and low-fat foods like bagels and Snackwell cookies. Despite this change, the rate of heart disease, diabetes, and obesity continued to grow.

Then the pendulum swung the other direction, with people adopting the Atkins diet and eating nothing but meat, cheese, and eggs. And then Atkins himself had a heart attack.

Part of the problem is that food is big money. So the Food Pyramid put out by the USDA is the product of very heavy lobbying efforts. Another part of the problem is that until now there has been no overriding paradigm about what good nutrition really is.

And so the low-fat vegetarian proponents eat their whole grains and soy burgers, thinking they are eating the right way, while others avoid carbs like the plaque. Who is right? Is the answer “moderation?“ And what is that?

Eating the Foods We Evolved To Eat

Imagine that you were a zoo keeper, and it was your job to keep the animals healthy. In one cage you‘ve got a giraffe, in another you‘ve got a lion, and in the third you have an anteater. What do you feed them?

Most people would answer that you try to feed them what they would eat in the wild. If you do so, you‘re most likely to have healthy animals. If you get things mixed up and feed the lion leaves, the giraffe ants, and the anteater meat, you‘ll have some sick

The Effects of a Regenerative Mitochondrial Medication on Physiological Parameters in Case of Diabetes Mellitus Type II
<b>Condition</b>:   Diabetes Mellitus, Type II<br/><b>Interventions</b>:   Dietary Supplement: Mitochondrial preparations;   Dietary Supplement: Infusion therapy;   Device: Webermedical device;   Behavioral: Nutritional therapy<br/><b>Sponsor</b>:   Center for Integrative Medicine, Germany<br/><b>Not yet recruiting</b> - verified September 2010
Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes: An Extention Trial to NN1250-3583
<b>Condition</b>:   Diabetes Mellitus, Type 1<br/><b>Interventions</b>:   Drug: NN1250;   Drug: insulin aspart;   Drug: insulin glargine<br/><b>Sponsor</b>:   Novo Nordisk<br/><b>Recruiting</b> - verified September 2010
Screen of DM by OGTT in Subjects Receiving CAG or MDCT for CAD
<b>Conditions</b>:   Diabetes Mellitus;   Coronary Artery Disease<br/><b>Intervention</b>:   Drug: Acarbose<br/><b>Sponsor</b>:   Taichung Veterans General Hospital<br/><b>Recruiting</b> - verified September 2010
A Surgical Approach to the Management of Type II Diabetes Mellitus in Patients With a BMI Between 25-35 kg/m2
<b>Condition</b>:   Type 2 Diabetes Mellitus<br/><b>Interventions</b>:   Procedure: Sleeve Gastrectomy and Ileal transposition;   Dietary Supplement: dietary and medical management<br/><b>Sponsor</b>:   The University of Texas Health Science Center, Houston<br/><b>Not yet recruiting</b> - verified September 2010
Sweetheart-Register: Risk Management of Diabetics With Acute Myocardial Infarction
<b>Conditions</b>:   Diabetes;   STEMI;   NSTEMI;   Myocardial Infarction<br/><b>Intervention</b>:   <br/><b>Sponsors</b>:   Stiftung Institut fuer Herzinfarktforschung;   Sanofi-Aventis Deutschland GmbH<br/><b>Completed</b> - verified September 2010
Feasibility Study to Assess the Safety and Functionality of the GluSense Continuous Glucose Monitor in Diabetic Patients
<b>Condition</b>:   Diabetes<br/><b>Intervention</b>:   Dietary Supplement: Boost Nutritional Supplement<br/><b>Sponsor</b>:   GluSense Ltd<br/><b>Not yet recruiting</b> - verified September 2010
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
<b>Condition</b>:   Type 2 Diabetes<br/><b>Interventions</b>:   Drug: Dapagliflozin;   Drug: Dapagliflozin;   Drug: Placebo<br/><b>Sponsors</b>:   Bristol-Myers Squibb;   AstraZeneca<br/><b>Not yet recruiting</b> - verified September 2010
Single-centre, Randomised, Double-blind, Placebo-controlled, Four-way Crossover Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Doses of CM3.1-AC100 in Patients With Type 2 Diabetes
<b>Condition</b>:   Type II Diabetes Mellitus<br/><b>Intervention</b>:   Drug: CM3.1-AC100<br/><b>Sponsor</b>:   CellMed AG, A Subsidiary of Biocompatibles International plc.<br/><b>Recruiting</b> - verified September 2010
Euglycemic Clamp Dose-response Study Comparing Insulin Glargine U300 With Lantus® U100
<b>Condition</b>:   Type 1 Diabetes Mellitus<br/><b>Interventions</b>:   Drug: Insulin glargine (HOE901);   Drug: Insulin glargine (HOE901)<br/><b>Sponsor</b>:   Sanofi-Aventis<br/><b>Recruiting</b> - verified September 2010
Efficacy of Adding Sitagliptin or Pioglitazone to T2DM Insufficiently Controlled With Metformin and Sulfonylurea
<b>Condition</b>:   Type 2 Diabetes<br/><b>Interventions</b>:   Drug: Sitagliptin;   Drug: pioglitazone<br/><b>Sponsor</b>:   Mackay Memorial Hospital<br/><b>Recruiting</b> - verified September 2010
Benefit/Risk Evaluation of Insuman Implantable Versus Insuplant Using Medtronic MiniMed Implantable Pump System in Patients With Type 1 Diabetes
<b>Condition</b>:   Diabetes Mellitus, Type 1<br/><b>Interventions</b>:   Drug: HUMAN INSULIN (BIOSYNTHETIC);   Drug: Insuplant<br/><b>Sponsor</b>:   Sanofi-Aventis<br/><b>Not yet recruiting</b> - verified September 2010
Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study
<b>Condition</b>:   Diabetes Mellitus, Type 2<br/><b>Interventions</b>:   Drug: Placebo;   Drug: Linagliptin<br/><b>Sponsor</b>:   Boehringer Ingelheim Pharmaceuticals<br/><b>Not yet recruiting</b> - verified September 2010
Behavioral Weight Loss as a Treatment for Migraine in Overweight Women
<b>Conditions</b>:   Migraine;   Obesity<br/><b>Intervention</b>:   Behavioral: Behavioral weight loss<br/><b>Sponsor</b>:   The Miriam Hospital<br/><b>Recruiting</b> - verified August 2010
Effect of Formoterol on the Counterregulatory Hormonal Response to Hypoglycemia
<b>Condition</b>:   Type 1 Diabetes<br/><b>Intervention</b>:   Drug: Formoterol<br/><b>Sponsors</b>:   Yale University;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)<br/><b>Recruiting</b> - verified September 2010
An Open-randomized, Balanced, Crossover Bioequivalence Study to Compare One MR Tablet of 60 mg Gliclazide and Two MR Tablets of 30 mg Gliclazide in Healthy Subjects
<b>Conditions</b>:   Hyperglycemia;   Diabetes<br/><b>Intervention</b>:   <br/><b>Sponsor</b>:   Taipei Medical University WanFang Hospital<br/><b>Recruiting</b> - verified September 2010
Insulin Administration Plus a Telemedicine System (Diabetes Interactive Diary - DID) vs Insulin Plus Common Practice
<b>Condition</b>:   Type 1 Diabetes<br/><b>Intervention</b>:   Device: Diabetes Interactive Diary (DID)<br/><b>Sponsors</b>:   Consorzio Mario Negri Sud;   Sanofi-Aventis;   LifeScan<br/><b>Recruiting</b> - verified September 2010
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus
<b>Condition</b>:   Diabetes Mellitus, Type II<br/><b>Intervention</b>:   Drug: Insulin LISPRO<br/><b>Sponsor</b>:   Halozyme Therapeutics<br/><b>Recruiting</b> - verified September 2010
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 1 Diabetes Mellitus
<b>Condition</b>:   Diabetes Mellitus, Type 1<br/><b>Intervention</b>:   Drug: Insulin LISPRO<br/><b>Sponsor</b>:   Halozyme Therapeutics<br/><b>Recruiting</b> - verified September 2010
Anterior and Posterior Segment Vascular Changes Following Laser and Anti-Vascular Endothelial Growth Factor (VEGF) Treatment of Diabetic Retinopathy
<b>Condition</b>:   Diabetic Macular Edema<br/><b>Intervention</b>:   <br/><b>Sponsors</b>:   University of Toronto;   Juvenile Diabetes Research Foundation<br/><b>Recruiting</b> - verified September 2010
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes: An Extension Trial to NN1250-3579
<b>Condition</b>:   Diabetes Mellitus, Type 2<br/><b>Interventions</b>:   Drug: NN1250;   Drug: insulin glargine<br/><b>Sponsor</b>:   Novo Nordisk<br/><b>Not yet recruiting</b> - verified August 2010
Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With or Without Metformin and With/Without Pioglitazone in Type 2 Diabetes: An Extension Trial to NN1250-3582
<b>Condition</b>:   Diabetes Mellitus, Type 2<br/><b>Interventions</b>:   Drug: NN1250;   Drug: insulin glargine;   Drug: insulin aspart<br/><b>Sponsor</b>:   Novo Nordisk<br/><b>Recruiting</b> - verified September 2010
BI 10773 Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus
<b>Condition</b>:   Diabetes Mellitus, Type 2<br/><b>Interventions</b>:   Drug: BI 10773;   Drug: BI 10773;   Drug: BI 10773;   Drug: BI 10773;   Drug: Placebo<br/><b>Sponsor</b>:   Boehringer Ingelheim Pharmaceuticals<br/><b>Not yet recruiting</b> - verified August 2010
Withdrawal of Immunosuppression in Long Term Stable Liver Transplant Recipients
<b>Condition</b>:   Liver Transplantation<br/><b>Interventions</b>:   Procedure: immunosuppression withdrawal;   Procedure: continue of taking immunosuppressant<br/><b>Sponsor</b>:   The Catholic University of Korea<br/><b>Recruiting</b> - verified July 2010
Risk Factors for Low Lymphocyte Count in Patients With Type 2 Diabetes
<b>Condition</b>:   Diabetes Mellitus, Type 2<br/><b>Intervention</b>:   <br/><b>Sponsors</b>:   Bristol-Myers Squibb;   AstraZeneca<br/><b>Active, not recruiting</b> - verified August 2010
A Study of OPC-262 in Patients With Type 2 Diabetes
<b>Condition</b>:   Diabetes, Type 2<br/><b>Intervention</b>:   Drug: OPC-262<br/><b>Sponsor</b>:   Otsuka Pharmaceutical Co., Ltd.<br/><b>Recruiting</b> - verified August 2010
Clinical Trial Evaluating the Efficacy and Safety of Technosphere Insulin Inhalation Power Using the Gen2 Inhaler
<b>Condition</b>:   Type 2 Diabetes<br/><b>Interventions</b>:   Drug: Technosphere Insulin;   Drug: Insulin Aspart;   Drug: Glargine<br/><b>Sponsor</b>:   Mannkind Corporation<br/><b>Not yet recruiting</b> - verified September 2010
Glycemic Holter Study (Continuous Glucose Monitoring) -
<b>Condition</b>:   Type 2 Diabetes Mellitus<br/><b>Interventions</b>:   Drug: Vildagliptin;   Drug: Sitagliptin<br/><b>Sponsor</b>:   Novartis<br/><b>Recruiting</b> - verified August 2010
Malignancy Meta Analysis for BRL49653
<b>Condition</b>:   Diabetes Mellitus, Type 2<br/><b>Intervention</b>:   Drug: allocation of treatment with metformin or rosiglitazone<br/><b>Sponsor</b>:   GlaxoSmithKline<br/><b>Completed</b> - verified September 2010
Psychosocial Interventions in the Treatment of Youth With Type 1 Diabetes Mellitus
<b>Condition</b>:   Diabetes Mellitus<br/><b>Intervention</b>:   Behavioral: psychosocial intervention<br/><b>Sponsor</b>:   Assaf-Harofeh Medical Center<br/><b>Recruiting</b> - verified August 2010
Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM)
<b>Condition</b>:   Type 2 Diabetes Mellitus<br/><b>Intervention</b>:   Drug: vildagliptin/metformin<br/><b>Sponsor</b>:   Novartis<br/><b>Recruiting</b> - verified September 2010
Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 × 500 mg Glucophage XR
<b>Condition</b>:   Diabetes Mellitus<br/><b>Interventions</b>:   Drug: saxagliptin;   Drug: Glucophage XR;   Drug: saxagliptin + metformin XR (FDC tablet)<br/><b>Sponsor</b>:   Bristol-Myers Squibb<br/><b>Completed</b> - verified August 2010
Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN)
<b>Condition</b>:   Diabetes Mellitus<br/><b>Interventions</b>:   Drug: saxagliptin;   Drug: metformin XR;   Drug: saxagliptin + metformin XR (FDC tablet)<br/><b>Sponsor</b>:   Bristol-Myers Squibb<br/><b>Completed</b> - verified August 2010
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-4)
<b>Condition</b>:   Diabetes Mellitus, Type 2<br/><b>Interventions</b>:   Drug: Insulin Glargine;   Drug: LY2189266<br/><b>Sponsor</b>:   Eli Lilly and Company<br/><b>Not yet recruiting</b> - verified August 2010
Comparison of NN1250 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes: An Extension Trial to NN1250-3585
<b>Condition</b>:   Diabetes Mellitus, Type 1<br/><b>Interventions</b>:   Drug: NN1250;   Drug: insulin detemir (Levemir®);   Drug: insulin aspart<br/><b>Sponsor</b>:   Novo Nordisk<br/><b>Recruiting</b> - verified September 2010
Exploratory Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes Mellitus and Secondary Hypogonadism or Adult-Onset Idiopathic Hypogonadotropic Hypogonadism
<b>Conditions</b>:   Type 2 Diabetes Mellitus;   Secondary Hypogonadism<br/><b>Interventions</b>:   Drug: Placebo;   Drug: enclomiphene citrate<br/><b>Sponsor</b>:   Repros Therapeutics Inc.<br/><b>Not yet recruiting</b> - verified September 2010
Dietary Intervention With Shop Model - SHOPUS
<b>Condition</b>:   Obesity<br/><b>Intervention</b>:   Behavioral: Dietary intervention<br/><b>Sponsor</b>:   University of Copenhagen<br/><b>Recruiting</b> - verified July 2010
Adipose Tissue Gene Expression Profiles in Women With Polycystic Ovary Syndrome (PCOS) Versus Controls
<b>Condition</b>:   Polycystic Ovary Syndrome<br/><b>Intervention</b>:   <br/><b>Sponsors</b>:   The Adelaide and Meath Hospital;   University College Dublin<br/><b>Completed</b> - verified July 2008
Cardiovascular Risk Markers in Polycystic Ovary Syndrome (PCOS)
<b>Condition</b>:   Polycystic Ovary Syndrome<br/><b>Intervention</b>:   <br/><b>Sponsors</b>:   The Adelaide and Meath Hospital;   University College Dublin<br/><b>Completed</b> - verified July 2008


animals very quickly.

So using the same thinking, what do you feed a human in order to keep him or her optimally healthy? The foods that they evolved to eat, of course.

For 2.5 million years humans lived as hunter gatherers. We ate whatever we could pick, find, or catch. So our diet consisted of fruits, vegetables, tubers, meat, and seafood. (And the occasional bug).

It was only 10,000 years ago (500 generations) that humans began eating grains (wheat, rice, corn, etc.) as a regular part of their diet. Dairy consumption (other than mother‘s milk) first began approximately 6000 years ago. The regular use of vegetable oils, refined sugar, and salt is even more recent. As I mentioned last month, two-thirds of the foods we now eat are foods that are new to our system, for which we are not genetically adapted.

Evolution moves quite slowly, and the simple fact is that we are not adapted to eating these foods, and they are making us sick.

The Problems With Grains

Grains are the seeds of grasses. The grass seed itself doesn‘t want to be eaten, because its purpose is to grow a new blade of grass. So it has various “anti-nutrients“ to protect it from pests and predators.

Protease inhibitors in wheat bind trypsin, preventing this digestive enzyme from digesting protein. A protein called wheat germ agglutin (WGA) happens to bind to a hormone receptor in the gut, entering circulation and causing an immediate immune reaction every time you eat a piece of bread.

WGA also increases gut permeability, increasing the likelihood that other undigested dietary components may enter circulation.

Another component found in cereals such as rye, oats, barley, and corn are “alkylresorcinols.“ These are thought to provide the seed resistance from pathogenic organisms, but they are also toxic to humans, and have been shown to cause red blood cell destruction and DNA damage.

Grains also raise blood sugar very rapidly, causing a high secretion of insulin from the pancreas. High circulating insulin is characteristic of “metabolic syndrome“, which a vast number of Americans currently suffer from.

What About Milk?

Cow milk contains a hormone called betacellulin, which binds to a receptor in the gut called the EGF receptor. Just one glass of milk has the capacity to stimulate the receptor 10 times as much would normally occur in 24 hours from EGF in the saliva.

When the EGF receptor is stimulated it causes the body to “upregulate“ EGF receptors, basically causing more of them to appear. This in turn let‘s even more betacellulin enter the body the next time you have some dairy. Upregulation of the EGF receptor is characteristic of many cancers, including breast, prostate, lung, ovarian, and bladder.

No animals other than humans consume milk past the age of weaning.

Prevent Autoimmune Disease

The incidence of autoimmune diseases increases as people age. It occurs when the body loses the ability to distinguish its own proteins from foreign proteins, and starts attacking itself.

Grains and beans contain substances called “lectins“, which are known to increase gut permeability, possibly allowing in gut bacteria substances that can trigger an autoimmune reaction.

Cereal grains and beans also contain proteins with amino acid sequences that are very similar to those found in human collagen and other tissues of the body. If the immune system gets confused, it can start attacking itself (such as with rheumatoid arthritis when joints become swollen and painful).

Get Rid Of Acne

Yes, even something as seemingly minor as acne can be prevented by eating a Paleo diet. Saving just $2000 in doctor visits over the next couple years could result in an extra $25,000 in your HSA by the time you finally decide to take the money out.

If these ideas intrigue you, check out www.ThePaleoDiet.com.

Article Source: http://www.ArticleJoe.com

By Wiley Long - President, HSA for America (www.health--savings--accounts.com“>www.health--savings--accounts.com) - The nation‘s leading independent health insurance firm specializing in individual and family coverage that work with www.health--savings--accounts.com“>Health Savings Accounts.

Here are some more diabetes articles...